Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Tatsuya Kamei
Institution:
Sumitomo Dainippon Pharma (Japan)
Observed institution:
Sumitomo Dainippon Pharma (Japan)
ORCID:
0009-0002-3418-5691
Observed ORCID:
0009-0002-3418-5691
OpenAlex ID:
A5075775369
Self-organization, quality control, and preclinical studies of human iPSC-derived retinal sheets for tissue-transplantation therapy
2023
·
Kenji Watari
, Suguru Yamasaki
, et al.
·
Communications Biology
·
69
PDF
Unique electrophysiological property of a novel Nav1.7, Nav1.8, and Nav1.9 sodium channel blocker, ANP-230
2024
·
Tatsuya Kamei
, Takehiro Kudo
, et al.
·
Biochemical and Biophysical Research Communications
·
18
A novel Nav1.7, Nav1.8, and Nav1.9 blocker, ANP-230, has broad analgesic efficacy in preclinical pain models with favorable safety margins
2025
·
Tatsuya Kamei
, Fumiaki Ishibashi
, et al.
·
Biochemical and Biophysical Research Communications
·
11
Partial Fluid-Air Exchange Enhances Submacular Injection of Retinal Sheets
2026
·
Grace Baldwin
, Yukari Akita
, et al.
·
Ophthalmic surgery, lasers & imaging retina
Show more works
View as search
Works count:
4
Citation count:
98
H-index:
3
I10-index:
3
Year
Topic
Type
